Mangoceuticals, Inc. (MGRX)

NASDAQ: MGRX · Real-Time Price · USD

2.370

+0.110 (4.87%)

At close: Nov 4, 2024, 4:00 PM

2.320

-0.050 (-2.11%)

After-hours: Nov 4, 2024, 6:03 PM EST

Mangoceuticals Employees

Mangoceuticals had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

3

Change (1Y)

1

Growth (1Y)

50.00%

Revenue / Employee

$288,931

Profits / Employee

-$3,042,022

Market Cap

5.61M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	0	-
Dec 31, 2021	2	-	-

Related Stocks

Company Name	Employees
IM Cannabis	95
ENDRA Life Sciences	21
Aethlon Medical	14
Eterna Therapeutics	8
Galmed Pharmaceuticals	8
CNS Pharmaceuticals	5
Creative Medical Technology Holdings	4
Evoke Pharma	4

Employee Rankings

MGRX News

14 days ago - MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly - GlobeNewsWire
17 days ago - Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024 - Newsfile Corp
18 days ago - Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter - Benzinga
24 days ago - MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN - GlobeNewsWire
4 weeks ago - MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions - GlobeNewsWire
4 weeks ago - MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment - GlobeNewsWire
2 months ago - MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024 - GlobeNewsWire
3 months ago - MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide - GlobeNewsWire